<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901391</url>
  </required_header>
  <id_info>
    <org_study_id>RU-RP-03-2019</org_study_id>
    <nct_id>NCT03901391</nct_id>
  </id_info>
  <brief_title>Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa</brief_title>
  <acronym>RU-RP</acronym>
  <official_title>Prospective Open Label Clinical and Genetic Testing of Patients With Retinitis Pigment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensor Technology for Deafblind</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Central Clinical Hospital under President Affairs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deaf-Blind Support Foundation Con-nection</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal State Budgetary Institution Moscow Helmholtz Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal State Budgetary Institution Research Center for Medical Genetics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oftalmic LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Genetics and Reproductive Medicine Genetico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sensor Technology for Deafblind</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to characterize Russian population of Retinitis Pigmentosa&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to characterize Russian population of Retinitis Pigmentosa.&#xD;
&#xD;
      Tasks:&#xD;
&#xD;
      Stage 1. Formation of the primary cohort of patients. Patients pre-recruiting will be&#xD;
      performed based on Deaf-Blind Support Foundation &quot;Con-nection&quot; patient database analysis and&#xD;
      from references. Patients with clinically confirmed Retinitis pigmentosa will be evaluated&#xD;
      according to available data of the clinical examination.&#xD;
&#xD;
      Stage 2. Genetic study of patients. All enrolled patients will undergo single 4 ml peripheral&#xD;
      venous blood sampling. DNA will be extracted from leucocytes. DNA samples will be analyzed&#xD;
      and placed for long-term storage in liquid nitrogen. Stage 3. Clinical examination of&#xD;
      patients.&#xD;
&#xD;
      Each patient will undergo the following diagnostic procedures according to the unified&#xD;
      protocol:&#xD;
&#xD;
        -  Visometry (with correction and without correction)&#xD;
&#xD;
        -  Ophthalmoscopy&#xD;
&#xD;
        -  Perimetry&#xD;
&#xD;
        -  Optical coherence tomography&#xD;
&#xD;
        -  Electroretinography&#xD;
&#xD;
        -  Visually evoked potentials&#xD;
&#xD;
        -  Refractometry&#xD;
&#xD;
        -  Pneumotonometry&#xD;
&#xD;
        -  Biomicroscopy&#xD;
&#xD;
        -  Any additional examinations and consultations if necessary Medical record will be&#xD;
           developed and maintained for each patient consisting results of extended clinical&#xD;
           examination.&#xD;
&#xD;
      Statistical and bioinformatic analysis of detected genetic mutations in the study cohort will&#xD;
      be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in visual acuity</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by visual acuity test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in structures of fundus of the eye-1</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by ophthalmoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in structures of fundus of the eye-2</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by ophthalmoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in visual field</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by perimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brain visual cortex neural pathways</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by visually evoked potentials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in electroretinogram</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by electroretinography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in optical refraction</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by refractometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in intraocular pressure</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by pneumotonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the lens, cornea, anterior segment of the eye</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by biomicroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in central retinal profile</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured by optical coherent tomography</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Usher Syndromes</condition>
  <arm_group>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Whole Exome Sequencing</intervention_name>
    <description>Whole Exome Sequencing</description>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It is assumed that at least 130 patients of the Russian population of men and women aged 6&#xD;
        to 65 years, with verified diagnosis of Retinitis pigmentosa (AD, AR, X-linked or sporadic&#xD;
        as defined by the Retinitis pigmentosa consortium), will take part in this research study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient fulfill the clinical characteristics for Retinitis Pigmentosa (AD, AR,&#xD;
             X-linked, sporadic) as defined by the Retinitis pigmentosa consortium&#xD;
&#xD;
          -  Results of perimetry for each eye show narrowing for 15 degrees or more.&#xD;
&#xD;
          -  Patient is familiar with Participant information sheet&#xD;
&#xD;
          -  Patient signed informed consent form&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Participation in other clinical trials (or administration of investigational drugs)&#xD;
             during 3 months prior inclusion&#xD;
&#xD;
          -  Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and&#xD;
             alcohol abuse etc.)&#xD;
&#xD;
          -  Medical history of traumatic injury of eyes, barotrauma, concussion, craniocerebral&#xD;
             trauma, cerebrovascular accident&#xD;
&#xD;
          -  Congenital multiple development orbit and eye malformations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal from the further participation in the trial&#xD;
&#xD;
          -  Decompensated diabetes mellitus&#xD;
&#xD;
          -  Severe coronary artery disease&#xD;
&#xD;
          -  Chronic infectious disease&#xD;
&#xD;
          -  Patients with malignant tumors including postoperative period, patients receiving&#xD;
             chemotherapy and/or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dmitry S. Atarshchikov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Clinical Hospital under President Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Moscow Helmholtz Research Institute of Eye Diseases&quot; of the Ministry of Health</name>
      <address>
        <city>Moscow</city>
        <zip>105062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital under President Affairs</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Usher Syndromes</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

